Genome-Wide Association Studies on Attention Deficit Hyperactivity Disorder

Kathryn Ashmore¹ and Feng Cheng²*

¹Department of Chemistry, University of South Florida, USA
²Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, USA

Abstract
A Genome-Wide Association Study (GWAS) is an approach to identify common genetic variations associated with a disease. It is widely used to determine the genetic basis of diseases. In this paper, the applications of GWAS on Attention Deficit Hyperactivity Disorder (ADHD) were reviewed.

Attention-Deficit Hyperactivity Disorder
ADHD is a psychiatric disease in children and adults characterized by inattention, impulsivity, and hyperactivity. It is estimated by the US Center for Disease Control (CDC) that three to seven percent of school aged children are diagnosed with ADHD. ADHD is a serious issue in classrooms and families because it affects not only the child, but his or her family, classmates, and teachers. Furthermore, children with the disorder often struggle in school due to their inability to focus for long periods of time. There is currently no efficient or cost-effective way to treat or diagnose this disorder because the mechanisms underlying ADHD remain unclear. ADHD is considered to be a highly heritable disorder from the previous family-based study [1]. The heritability of this disease is about 0.8 [2]. However, it is difficult to identify genes or susceptibility loci associated with the disorder. Therefore, new research and clinical studies are imperative and invaluable.

Genome-Wide Association Studies
GWAS have been conducted on ADHD to detect common genetic variants, including Single-Nucleotide Polymorphism (SNP) and Copy Number Variation (CNV), to see if there are any genes involved in ADHD. GWAS has the potential to find novel disease-related genes because it investigates all human genes in the whole genome instead of specific genes or chromosome regions. GWAS is therefore referred to as a non-candidate-gene-driven study. In the NIH GWAS database (http://www.genome.gov/26525384), 8,175 SNPs from 1,476 GWAS publications had reached genome-wide significance (p-value ≤ 5 × 10⁻⁸) as a non-candidate-gene-driven study. In the NIH GWAS database (http://www.genome.gov/26525384), 8,175 SNPs from 1,476 GWAS publications had reached genome-wide significance (P-value ≤ 5 × 10⁻⁸) for over 200 diseases by January 2013. In this paper, we will review some progress in GWAS on ADHD.

GWAS have two experimental designs based on the sample collection: unrelated case-control design and family-based design (triplet design). In the former design, patients (cases) and unrelated participants without the disease (controls) are selected. A linear regression is performed to test associations of SNPs and disease status. If a SNP is more frequent in patients than in controls, the SNP might be considered to be “associated” with the disease. The unrelated case-control design is simple and widely used. The disadvantage of this design is the population stratification bias (or confounding by race/ethnicity) that could bring false positives. In the family-based design, ADHD patients and their parents (triplet members) are chosen. The frequency of an allele transmitted from heterozygous parents to affected offspring is calculated. The population stratification bias can be bypassed in the family-based design because family members have a similar genetic background and environmental effects. The limitation of the family-based design is the difficulty of collecting large numbers of family samples.

Applications of GWAS on ADHD
Recently, large scale genome-wide association studies [2-10] have been applied to identify novel ADHD risk genes using either unrelated case-control or family-based design (Table 1). An unrelated case-control GWAS was conducted on adult ADHD patients using Affymetrix Human Mapping 500K SNP microarray by Lesch et al. [3]. Samples from 343 adult ADHD patients and 250 controls of German origin were investigated in this study. There was no SNP that reached stringent genome-wide significance. However, among the gene list derived from the 30 highest ranking SNPs, genes (such as CDH13, ASTN2, and CTNNA2) identified by the GWAS in other neuro developmental and psychiatric disorders were also shown. The first case-control GWAS was performed on children and adolescents by Neale et al. [4]. DNA samples from 896 young ADHD patients and 2,455 controls of European origin were collected by the International Multicenter ADHD Genetics (IMAGE) project from Europe and the USA. 1,033,244 SNPs were analyzed in this study and the best SNP was rs10823973 located in PRKGIa1 chromosome 10 and its p-value was 6.32 × 10⁻⁸. Hinney et al. [2] performed an unrelated case-control on 495 German ADHD children/adolescents and 1,300 controls. 11,917 X-chromosomal and 487,484 autosomal SNPs were investigated and the lowest p-value was 8.37 × 10⁻⁷ at the SNP rs2556378. Although no genome-wide significance (p-value ≤ 5 × 10⁻⁸) was detected, gene, GRM5 identified from the top 30 SNPs, has been reported as a candidate gene by previous studies. Stergiakouli et al. [5] performed a GWAS based on 727 Caucasian children with ADHD and 5,081 controls from the United Kingdom and Ireland. 518,511 SNPs were analyzed and the lowest p-value was 6.38 × 10⁻⁶ at rs11698703. CHRNA7, one of the nicotinic acetylcholine receptors, was believed to be a promising candidate gene.

CNV analysis showed CHRNA7 had six large duplications in ADHD patients and none in the control people. The smallest p-value of SNP in this gene was 0.0002.

Several family-based GWAS studies also have been conducted

*Corresponding author: Feng Cheng, Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, USA, Tel: 813-974-4288; Fax: 813-905-9890; E-mail: fcheng1@health.usf.edu

Received January 25, 2013; Accepted February 11, 2013; Published February 14, 2013


Copyright: © 2013 Ashmore K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
to identify ADHD-related genes. Neale et al. analyzed about 438,784 SNPs in 909 parent-offspring trios of European descent. Similar to the unrelated case-control studies, no SNPs showed genome-wide significance. Lantieri et al. [10] validated the 36 top genes of Neale’s family-based study using 415 independent trios in the USA. They found two SNPs were significant at α=0.05 in this independent test set. These significant SNPs are located at the coding regions of XKR4 and FAM190A. Lasky-Su et al. [7] investigated 429,981 autosomal SNPs in 930 European trios. The lowest p-value was 1.02 × 10^-7 at rs9451437 found two SNPs were significant at α=0.05 in this independent test set. Similar to Neale’s family-based GWAS led to the identification of significant ADHD-related SNPs at the genome-wide level. There were some explanations for the negative GWAS findings [5,6,9,11]. First, ADHD might be a multifactorial disorder caused by some common genetic variants with small effect sizes. These variants could not be well detected with genome-wide statistical confidence at current sample sizes. Second, although combining samples from different GWAS studies could increase the sample size, inconsistent genotyping platforms and ADHV evaluation criteria might eliminate positive findings. Thirdly, ADHD might be caused by rare (or low frequency) alleles that cannot be well detected by SNP microarrays. With the development of the next generation sequencing, whole genome or exome sequencing will provide an opportunity to capture these rare variants. Fourth, there might be multiple ADHD subtypes which have different genetic mechanisms. The genetic heterogeneity might dilute the effects of real ADHD SNPs.

**Prospective**

Although recently published GWAS data have failed to identify genome-wide significant ADHD-related SNPs and genes, they provided some promising candidate genes and chromosome loci for further validation. These GWAS data sets could be pooled together for larger-scale meta-analyses. Additionally, multi-site collaborations and standardized protocols are necessary for collecting larger ADHD patient data sets in the future.

**Acknowledgements**

This work was supported by the start-up grant from the College of Pharmacy at the University of South Florida.

**Reference**


---

**Table 1:** Large scale genome-wide association studies on attention-deficit hyperactivity disorder.

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Sample Size</th>
<th>Promising Candidate Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neale [4]</td>
<td>Case-control</td>
<td>896/2,455</td>
<td>PRKG1, FLNC, TCERG1L, PPM1H, NPH1, PPM1H, CDH13, HK1, and HKDC1</td>
</tr>
<tr>
<td>Hinney [2]</td>
<td>Case-control</td>
<td>495/1,300</td>
<td>GRM5</td>
</tr>
<tr>
<td>Stergiakouli [5]</td>
<td>Case-control</td>
<td>727/5,081</td>
<td>CHRNA7</td>
</tr>
<tr>
<td>Neale [6]</td>
<td>Family</td>
<td>909 trios</td>
<td>XKR4, and FAM190A</td>
</tr>
<tr>
<td>Mick [8]</td>
<td>Family</td>
<td>735 trios</td>
<td>SLC9A9</td>
</tr>
<tr>
<td>Neale [9]</td>
<td>Combined</td>
<td>2,064 trios and 896/2,455</td>
<td>CHMP7, TNFRSF10D, TNFRSF10A, and LOXL2</td>
</tr>
</tbody>
</table>

**Citation:** Ashmore K, Cheng F (2013) Genome-Wide Association Studies on Attention Deficit Hyperactivity Disorder. Clin Exp Pharmacol 3: 119. doi:10.4172/2161-1459.1000119